Home » Stocks » ATNM

Actinium Pharmaceuticals, Inc. (ATNM)

Stock Price: $10.84 USD 0.44 (4.23%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $11.20 +0.36 (3.32%) Dec 4, 7:38 PM

ATNM Stock Price Chart

Key Info

Market Cap 147.28M
Revenue (ttm) n/a
Net Income (ttm) -20.44M
Shares Out 15.43M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $10.84
Previous Close $10.40
Change ($) 0.44
Change (%) 4.23%
Day's Open 10.36
Day's Range 10.16 - 10.87
Day's Volume 409,019
52-Week Range 0.18 - 12.64

ATNM Stock News

Seeking Alpha - 19 hours ago

Additional early stage results continue to be promising. The cash balance is adequate.

Zacks Investment Research - 2 days ago

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.35, marking a +0.78% move from the previous day.

PRNewsWire - 1 week ago

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab...

Zacks Investment Research - 2 weeks ago

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.

PRNewsWire - 2 weeks ago

NEW YORK, Nov. 19, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Avinash Desai, MD, to the position of Executive Vic...

PRNewsWire - 2 weeks ago

NEW YORK, Nov. 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual...

Zacks Investment Research - 3 weeks ago

Actinium Pharmaceuticals (ATNM) closed at $12.01 in the latest trading session, marking a +0.5% move from the prior day.

PRNewsWire - 1 month ago

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) ...

PRNewsWire - 1 month ago

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/...

Zacks Investment Research - 1 month ago

Is (ATNM) Outperforming Other Medical Stocks This Year?

PRNewsWire - 1 month ago

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab fa...

Zacks Investment Research - 1 month ago

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.

Seeking Alpha - 2 months ago

Their targeted approach to bone marrow transplant conditioning has shown early signs of significantly improving on the poor outcomes seen with current non-targeted therapies.

Zacks Investment Research - 3 months ago

Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 3 months ago

Is (ATNM) Outperforming Other Medical Stocks This Year?

PRNewsWire - 3 months ago

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.

Zacks Investment Research - 3 months ago

Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 4 months ago

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -1.67% move from the previous day.

Zacks Investment Research - 4 months ago

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in Actinium Pharmaceuticals, Inc. (ATNM).

Zacks Investment Research - 4 months ago

Actinium Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 4 months ago

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ALPN, PCRX, TBIO
Zacks Investment Research - 5 months ago

Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.

Zacks Investment Research - 5 months ago

Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 5 months ago

Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 8 months ago

Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

Zacks Investment Research - 9 months ago

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

Zacks Investment Research - 10 months ago

Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 1 year ago

Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

About ATNM

Actinium Pharmaceuticals, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle dru... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Sandesh Seth
Stock Exchange
NYSE American
Ticker Symbol
ATNM
Full Company Profile

Financial Performance

Financial Statements